2025 Q4 -tulosraportti
37 päivää sitten
‧1 t 12 min
7,95 DKK/osake
Irtoamispäivä 27.3.
4,72%Tuotto/v
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 75 | - | - | ||
| 74 | - | - | ||
| 25 | - | - | ||
| 6 | - | - | ||
| 27 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 702 261 | 1 702 261 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 702 261 | 1 702 261 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 6.8.2025 | ||
2025 Q1 -tulosraportti 7.5.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·44 min sittenA wedge formation has built up over the last week, wants an upward breakout now, with force. Happy Weekend!
·1 t sittenOn 1 April 2021, the price was DKK 226.52, today it is approximately DKK 250.00. The company will with high probability have a significantly higher net profit after tax in the coming five years, on average, than it had in the financial year 2021. Unless completely new events occur regarding the competitive situation, I cannot understand anything other than that today's price is low compared to the historical price. This means that if we remain calm now, and give it time, this will be a very good investment.
·50 min sitten · MuokattuIMHO, the biggest problem for the stock right now is all the shareholders who already held the stock before various downturns began. Their liquidity is tied up in Novo and indirectly prevents them from buying (especially many) more shares. For the stock to rise, new investors are needed (and the old ones must refrain from realizing their losses). New investors are constantly coming in, but not all at once, so what is happening in these weeks is some kind of equalization of the balance in the above. The new investors proceed cautiously, and some of the old ones continue to sell off (and some of the new ones regret and/or take a quick small profit).·2 min sitten · MuokattuYep, and you're right about that. Therefore, I deleted my answer. The reason I don't find that the falling revenue is the biggest problem for the stock now is very simply because that "news" is almost a month old, and the stock already reacted back then when it became known with a big drop (and subsequently again). The first drop (after new guidance) was, in my opinion, completely appropriate. The second drop with the CagriSema figures I find overdone in relation to how much the stock has otherwise fallen. So - In my opinion, the biggest problem for the share price right now is what I'm writing (and therefore I own the stock).
·2 t sittenA comparison of the launch of the different weight loss medications on the market. It shows that the pill has grown faster than Zepbound. TRx = NRx (New Prescriptions) + Refills
·1 t sittenI assume that one should add the numbers together and then Novo's pill is up to 368.567 prescriptions after 9 weeks, while Zepbound only had 254.062. Week 4 and week 8 Zepbound has declined and therefore I think that one should add the prescription numbers together to get the total number of prescriptions. If Novo's pill costs 1.000 kr. per month, that corresponds to 6,6 billion kr. per year, of which Novo perhaps gets 25%, which almost goes straight to the bottom line. And in addition to that come all the pills outside the prescription numbers. Wow, that must bring in a lot of money.
·17 min sittenWasn't $299 the new price per month? 25% of 1000kr feels like a low estimate? Then of course there are some people who switch from previous novo-medicin that doesn't give the same bonus at the checkout. But prescriptions are increasing every week, so just calculating at the current level significantly underestimates the potential.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
37 päivää sitten
‧1 t 12 min
7,95 DKK/osake
Irtoamispäivä 27.3.
4,72%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·44 min sittenA wedge formation has built up over the last week, wants an upward breakout now, with force. Happy Weekend!
- ·1 t sittenOn 1 April 2021, the price was DKK 226.52, today it is approximately DKK 250.00. The company will with high probability have a significantly higher net profit after tax in the coming five years, on average, than it had in the financial year 2021. Unless completely new events occur regarding the competitive situation, I cannot understand anything other than that today's price is low compared to the historical price. This means that if we remain calm now, and give it time, this will be a very good investment.·50 min sitten · MuokattuIMHO, the biggest problem for the stock right now is all the shareholders who already held the stock before various downturns began. Their liquidity is tied up in Novo and indirectly prevents them from buying (especially many) more shares. For the stock to rise, new investors are needed (and the old ones must refrain from realizing their losses). New investors are constantly coming in, but not all at once, so what is happening in these weeks is some kind of equalization of the balance in the above. The new investors proceed cautiously, and some of the old ones continue to sell off (and some of the new ones regret and/or take a quick small profit).·2 min sitten · MuokattuYep, and you're right about that. Therefore, I deleted my answer. The reason I don't find that the falling revenue is the biggest problem for the stock now is very simply because that "news" is almost a month old, and the stock already reacted back then when it became known with a big drop (and subsequently again). The first drop (after new guidance) was, in my opinion, completely appropriate. The second drop with the CagriSema figures I find overdone in relation to how much the stock has otherwise fallen. So - In my opinion, the biggest problem for the share price right now is what I'm writing (and therefore I own the stock).
- ·2 t sittenA comparison of the launch of the different weight loss medications on the market. It shows that the pill has grown faster than Zepbound. TRx = NRx (New Prescriptions) + Refills·1 t sittenI assume that one should add the numbers together and then Novo's pill is up to 368.567 prescriptions after 9 weeks, while Zepbound only had 254.062. Week 4 and week 8 Zepbound has declined and therefore I think that one should add the prescription numbers together to get the total number of prescriptions. If Novo's pill costs 1.000 kr. per month, that corresponds to 6,6 billion kr. per year, of which Novo perhaps gets 25%, which almost goes straight to the bottom line. And in addition to that come all the pills outside the prescription numbers. Wow, that must bring in a lot of money.·17 min sittenWasn't $299 the new price per month? 25% of 1000kr feels like a low estimate? Then of course there are some people who switch from previous novo-medicin that doesn't give the same bonus at the checkout. But prescriptions are increasing every week, so just calculating at the current level significantly underestimates the potential.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 75 | - | - | ||
| 74 | - | - | ||
| 25 | - | - | ||
| 6 | - | - | ||
| 27 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 702 261 | 1 702 261 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 702 261 | 1 702 261 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 6.8.2025 | ||
2025 Q1 -tulosraportti 7.5.2025 |
2025 Q4 -tulosraportti
37 päivää sitten
‧1 t 12 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 6.8.2025 | ||
2025 Q1 -tulosraportti 7.5.2025 |
7,95 DKK/osake
Irtoamispäivä 27.3.
4,72%Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·44 min sittenA wedge formation has built up over the last week, wants an upward breakout now, with force. Happy Weekend!
- ·1 t sittenOn 1 April 2021, the price was DKK 226.52, today it is approximately DKK 250.00. The company will with high probability have a significantly higher net profit after tax in the coming five years, on average, than it had in the financial year 2021. Unless completely new events occur regarding the competitive situation, I cannot understand anything other than that today's price is low compared to the historical price. This means that if we remain calm now, and give it time, this will be a very good investment.·50 min sitten · MuokattuIMHO, the biggest problem for the stock right now is all the shareholders who already held the stock before various downturns began. Their liquidity is tied up in Novo and indirectly prevents them from buying (especially many) more shares. For the stock to rise, new investors are needed (and the old ones must refrain from realizing their losses). New investors are constantly coming in, but not all at once, so what is happening in these weeks is some kind of equalization of the balance in the above. The new investors proceed cautiously, and some of the old ones continue to sell off (and some of the new ones regret and/or take a quick small profit).·2 min sitten · MuokattuYep, and you're right about that. Therefore, I deleted my answer. The reason I don't find that the falling revenue is the biggest problem for the stock now is very simply because that "news" is almost a month old, and the stock already reacted back then when it became known with a big drop (and subsequently again). The first drop (after new guidance) was, in my opinion, completely appropriate. The second drop with the CagriSema figures I find overdone in relation to how much the stock has otherwise fallen. So - In my opinion, the biggest problem for the share price right now is what I'm writing (and therefore I own the stock).
- ·2 t sittenA comparison of the launch of the different weight loss medications on the market. It shows that the pill has grown faster than Zepbound. TRx = NRx (New Prescriptions) + Refills·1 t sittenI assume that one should add the numbers together and then Novo's pill is up to 368.567 prescriptions after 9 weeks, while Zepbound only had 254.062. Week 4 and week 8 Zepbound has declined and therefore I think that one should add the prescription numbers together to get the total number of prescriptions. If Novo's pill costs 1.000 kr. per month, that corresponds to 6,6 billion kr. per year, of which Novo perhaps gets 25%, which almost goes straight to the bottom line. And in addition to that come all the pills outside the prescription numbers. Wow, that must bring in a lot of money.·17 min sittenWasn't $299 the new price per month? 25% of 1000kr feels like a low estimate? Then of course there are some people who switch from previous novo-medicin that doesn't give the same bonus at the checkout. But prescriptions are increasing every week, so just calculating at the current level significantly underestimates the potential.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 75 | - | - | ||
| 74 | - | - | ||
| 25 | - | - | ||
| 6 | - | - | ||
| 27 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 702 261 | 1 702 261 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 702 261 | 1 702 261 | 0 | 0 |